Lite Strategy (LITS) Non-Current Deffered Revenue (2016 - 2023)
Lite Strategy (LITS) posted quarterly Non-Current Deffered Revenue of $64.5 million for Q2 2023, down 28.77% year-over-year from $90.6 million in Q2 2022, and little changed quarter-over-quarter from $64.5 million in Q1 2023.
Lite Strategy (LITS) Non-Current Deffered Revenue (2016 - 2023) Analysis & Trends
Lite Strategy's Non-Current Deffered Revenue history runs 7 years deep, the most recent figure standing at $64.5 million for Q2 2023.
- In Q2 2023, Non-Current Deffered Revenue fell 28.77% year-over-year to $64.5 million; the TTM figure through Jun 2023 stood at $64.5 million (down 28.77% YoY), while the FY2023 annual figure was $64.5 million, down 28.77% from the prior year.
- Non-Current Deffered Revenue for Q2 2023 stood at $64.5 million, roughly flat from $64.5 million in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $94.3 million in Q3 2021, with the low at $2.8 million in Q1 2020.
- The 5-year median for Non-Current Deffered Revenue is $69.6 million (2021), against an average of $54.4 million.
- The sharpest annual moves came in 2019 and 2020: Non-Current Deffered Revenue plunged 39.78% in 2019, then surged 2682.12% in 2020.
- Lite Strategy's Non-Current Deffered Revenue stood at $3.1 million in 2019, then soared by 2329.38% to $75.5 million in 2020, then climbed by 22.23% to $92.3 million in 2021, then sank by 30.07% to $64.5 million in 2022, then changed by 0.0% to $64.5 million in 2023.
- Business Quant data shows LITS's Non-Current Deffered Revenue at $64.5 million in Q2 2023, $64.5 million in Q1 2023, and $64.5 million in Q4 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Lite Strategy | 35.71 Mn | 28.17 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 64.55 Mn |
| Mar 31, 2023 | 64.55 Mn |
| Dec 31, 2022 | 64.55 Mn |
| Sep 30, 2022 | 89.97 Mn |
| Jun 30, 2022 | 90.61 Mn |
| Mar 31, 2022 | 91.92 Mn |
| Dec 31, 2021 | 92.29 Mn |
| Sep 30, 2021 | 94.33 Mn |
| Jun 30, 2021 | 74.70 Mn |
| Mar 31, 2021 | 4.30 Mn |
| Dec 31, 2020 | 75.51 Mn |
| Sep 30, 2020 | 76.98 Mn |
| Jun 30, 2020 | 78.43 Mn |
| Mar 31, 2020 | 2.82 Mn |
| Dec 31, 2019 | 3.11 Mn |
| Sep 30, 2019 | 3.23 Mn |
| Jun 30, 2019 | 2.82 Mn |
| Mar 31, 2019 | 4.22 Mn |
| Dec 31, 2018 | 5.16 Mn |
| Sep 30, 2016 | 1.49 Mn |